16205-98-4

Basic information

• Product Name: 3-OXO-1-CYCLOHEXANECARBOXYLIC ACID 96
• Synonyms: 3-OXO-1-CYCLOHEXANECARBOXYLIC ACID 96;3-oxo-cyclohexanecarboxylic acid;3-Ketocyclohexyl carboxylate;3-Carboxycyclohexan-1-one;Cyclohexanecarboxylic acid, 3-oxo-;1-Carboxy-3-oxocyclohexane;3-oxocyclohexanecarboxylate
• CAS NO: 16205-98-4
• Molecular Formula: C₇H₁₀O₃
• Molecular Weight: 142.1525
• Product Categories: Carboxylic Acids;Carboxylic Acids;Ring Systems;C7;Carbonyl Compounds
• Mol File: 16205-98-4.mol
• Article Data: 16

Chemical Properties

• Melting Point: 76 °C
• Boiling Point: 309.7 °C at 760 mmHg
• Flash Point: 155.3 °C
• Appearance: /
• Density: 1.233 g/cm³
• Vapor Pressure: 0.00014mmHg at 25°C
• Refractive Index: 1.5
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.72±0.20(Predicted)
• CAS DataBase Reference: 3-OXO-1-CYCLOHEXANECARBOXYLIC ACID 96(CAS DataBase Reference)
• NIST Chemistry Reference: 3-OXO-1-CYCLOHEXANECARBOXYLIC ACID 96(16205-98-4)
• EPA Substance Registry System: 3-OXO-1-CYCLOHEXANECARBOXYLIC ACID 96(16205-98-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 16205-98-4(Hazardous Substances Data)

Usage

Uses

3-Oxo-1-cyclohexanecarboxylic acid (3-oxocyclohexanecarboxylic acid) may be used in the preparation of 9-(4-chlorobenzoyl)-6-methoxy-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid by reacting with 4-chloro-N-(4-methoxyphenyl)benzohydrazide hydrochloride via Fischer indolization.

General Description

3-Oxo-1-cyclohexanecarboxylic acid is a cyclic keto acid that can be prepared starting from 2-acetoxy-1,4-ethoxycarbonylcyclohex-1-ne.

InChI:InChI=1/C7H10O3/c8-6-3-1-2-5(4-6)7(9)10/h5H,1-4H2,(H,9,10)

Upstream product

• 930-68-7 cyclohexenone 
• 124-38-9 carbon dioxide 
• 10265-39-1 7,7-dimethoxynorbornan-2-one 
• 586-38-9 3-Methoxybenzoic acid 
• 64-17-5 ethanol 
• 7664-41-7 ammonia 
• 7647-01-0 hydrogenchloride 
• 72453-13-5 2-oxo-cyclohexane-1,4-dicarboxylic acid diethyl ester 
• 10265-41-5 (1RS,2RS,4SR)-7,7-dimethoxybicyclo[2.2.1]heptan-2-ol 
• 64145-55-7 (+/-)-(1S,2S,4S)-7,7-dimethoxybicyclo[2.2.1]hept-5-en-2-ol 
• 54396-74-6 3-oxocyclohex-1-ene-1-carboxylic acid methyl ester 
• 17983-30-1 (RS)-3-oxocyclohexanecarbonitrile 
• 99-06-9 3-Carboxyphenol 
• 606488-94-2 3-hydroxycyclohexane-1-carboxylic acid 

Downstream Products

• 21531-47-5 3-oxo-cyclohexanecarboxylic acid methyl ester 
• 907594-36-9 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylic acid (1-phenylethyl)amide 
• 81131-39-7 (+/-)-cis-3-Aminocyclohexanecarboxylic acid 
• 81086-74-0 (R)-hydroxyiminocyclohexanecarboxylic acid 
• 101567-40-2 1-hydroxy-cyclohexane-1r,3t-1,3-dicarboxylic acid 
• 246-99-1 cyclopenta[b]indole 
• 942-01-8 1,2,3,4-tetrahydrocarbazole 
• 123762-08-3 3-oxocyclohexanecarboxylic acid benzyl ester 
• 1296113-72-8 9-(3-chloro-phenyl)-1,4-dioxa-9-aza-dispiro[4.1.4.3]tetradecan-8-one 
• 1296113-77-3 7-[2-(3-chloro-phenylamino)-ethyl]-1,4-dioxa-spiro[4.5]decane-7-carboxylic acid ethyl ester 
• 1296113-78-4 2-(3-chloro-phenyl)-2-aza-spiro[4.5]decane-1,7-dione 
• 412025-07-1 ethyl 1,4-dioxaspiro[4.5]decane-7-carboxylate 
• 37722-82-0 methyl 3-hydroxycyclohexanecarboxylate 
• 1332707-08-0 methyl 3-{[1-(biphenyl-4-ylmethyl)-4,6-difluoro-5-iodo-1H-benzimidazol-2-yl]oxy}cyclohexanecarboxylate 

Relevant articles and documents

Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof

The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity

Inhibiting the protein-protein interaction (PPI) between the transcription factor Nrf2 and its repressor protein Keap1 has emerged as a promising strategy to target oxidative stress in diseases, including central nervous system (CNS) disorders. Numerous non-covalent small-molecule Keap1-Nrf2 PPI inhibitors have been reported to date, but many feature suboptimal physicochemical properties for permeating the blood-brain barrier, while others contain problematic structural moieties. Here, we present the first side-by-side assessment of all reported Keap1-Nrf2 PPI inhibitor classes using fluorescence polarization, thermal shift assay, and surface plasmon resonance - and further evaluate the compounds in an NQO1 induction cell assay and in counter tests for nonspecific activities. Surprisingly, half of the compounds were inactive or deviated substantially from reported activities, while we confirm the cross-assay activities for others. Through this study, we have identified the most promising Keap1-Nrf2 inhibitors that can serve as pharmacological probes or starting points for developing CNS-active Keap1 inhibitors.

IRAK INHIBITORS AND USES THEREOF

The present invention provides arylo-fused thienopyrimidine compounds, compositions thereof, and methods of using the same.